Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
WARREN, N.J., Feb. 07, 2017 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for Tadalafil Oral Soluble Film (Tadalafil OSF) for the treatment of erectile dysfunction. The Tadalafil OSF NDA has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 18, 2017.
“The acceptance of the NDA and assignment of a PDUFA target action date is an important milestone that puts Tadalafil OSF one step closer to potential approval,” said Dan Barber, Vice President of MonoSol Rx. “Based on the success of our pivotal pharmacokinetic study in 2016 and our status as the first film alternative to tadalafil tablets to file for FDA approval, we believe that our product has significant potential and is well-positioned to compete in the multi-billion dollar erectile dysfunction market. Through our engagement with ESC Advisors, we are continuing to explore partnership opportunities for Tadalafil OSF and look forward to advancing this process as we move closer to our PDUFA date.”
Tadalafil is a PDE5 inhibitor currently marketed in tablet form for the treatment of erectile dysfunction and benign prostatic hyperplasia (BPH) under the brand name Cialis®, and for treatment of pulmonary arterial hypertension under the brand name Adcirca®. Tadalafil OSF will be offered in single pack doses and is expected to have several Orange Book listed patents upon approval.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, convenience, and compliance of pharmaceutical products. MonoSol Rx's leadership in film drug technology is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com.
Contact MonoSol Rx Jessica Patel [email protected] The Ruth Group Lee Roth [email protected] (646) 536-7012
